RGNX
NASDAQ HealthcareREGENXBIO Inc. - Common Stock
Biotechnology
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
�� 市场数据
| 价格 | $9.49 |
|---|---|
| 成交量 | 434,784 |
| 市值 | 489.85M |
| 贝塔系数 | 1.130 |
| RSI（14日） | 80.4 超买 |
| 200日均线 | $10.52 |
| 50日均线 | $8.75 |
| 52周最高 | $16.19 |
| 52周最低 | $5.85 |
| Forward P/E | -4.32 |
| Price / Book | 4.70 |
🎯 投资策略评分
RGNX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (73/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🐋 Institutional Whale (13/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 RGNX in your text
粘贴任何文章、记录或帖子 — 工具将提取 RGNX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.